Watson Says Barr Infringes Patent For Oxytrol

Law360, New York (October 24, 2008, 12:00 AM EDT) -- Watson Laboratories Inc. has slapped generic drug manufacturer Barr Pharmaceuticals Inc. with a patent infringement lawsuit over its application to market a generic version of Oxytrol, an overactive bladder treatment.

Watson filed the lawsuit on Wednesday in the U.S. District Court of Delaware after Barr filed an abbreviated new drug application requesting approval to market and sell a generic version of Oxytrol, a skin patch that releases oxybutynin into the bloodstream to treat OAB.

In the complaint, Watson said the alleged infringement would cause “irreparable harm”...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.